Big biotech, Biotech, Medical device, Partnering, Pharma

Rockwell forms a biotech partnership with Baxter for $45 million

Posted on 06 October 2014

Tags: , , , ,

Baxter International gave kidney drug developer Rockwell Medical a big boost in the form of $45 million in graduated payments in a biotech partnership.

The agreement gives Rockwell $20 million in cash, a $15 million investment in the company and another $10 million in potential milestone payments in exchange for Baxter’s exclusive distribution rights on its hemodialysis concentrate drugs.

Baxter also has the option to extend the agreement for two additional 5-year terms upon meeting certain sales targets, coupled with a $7.5 million payment related to the first extension.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Baxter

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Partnering Deals and Alliances with Big Biotech

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply